Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 8/20 | 0.41 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15876486 | 0.86 | KDM4E (0.60) | MAPTFAAHMEN1KMT2ALMNA | |
| SCHEMBL15796306 | 0.86 | KDM4E (0.60) | MAPTFAAHMEN1KMT2ALMNA | |
| SCHEMBL4143719 | 0.81 | MAPT (0.59) | MAPTFAAHCES1MEN1KMT2A | |
| SCHEMBL9279130 | 0.81 | MAPT (0.59) | MAPTFAAHCES1MEN1KMT2A | |
| SCHEMBL8460417 | 0.80 | KDM4E (0.56) | MAPTFAAHMEN1KMT2ALMNA | |
| SCHEMBL8345313 | 0.79 | DGKA (0.65) | FAAHCES1MEN1KMT2ACES2 | |
| SCHEMBL15876485 | 0.77 | MEN1 (0.42) | MAPTFAAHCES1MEN1KMT2A | |
| SCHEMBL17338126 | 0.77 | MAPT (0.54) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL68742 | 0.77 | MAPT (0.54) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL15261386 | 0.77 | MAPT (0.54) | MAPTMEN1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383380-B1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2023-01-04 | — | — | EP | disclosed |
| US-20190284129-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2019-09-19 | — | — | US | disclosed |
| US-20180346408-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2018-12-06 | — | — | US | disclosed |
| EP-3383380-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | Biozep AS (NO) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093732-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284129-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | APOB, ALOX12, NR1H2 | MAPT 3289/4885FAAH 139/4885CES1 153/4885 |
| US-20180346408-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | NR1H2, NR1H3, APOB | MAPT 2545/4885FAAH 234/4885CES1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.